Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$75,350.00
Total Gain % 149.43%
Total Gain $25,350.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
33 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $75,350.00
Total Gain $25,350.00
(149.43%)
Value $42,315.00
Close Price (13 Apr) $141.05
Unrealised P/L (%) 149.40%
Unrealised P/L $25,350.00
Total $75,350.00
$25,350.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $64.95
Added Price $43.06
STRIDE Rating 36
Value Change (%) 50.85%
Current Price $33.88
Added Price $34.64
STRIDE Rating 25
Value Change (%) -2.19%
Current Price $26.74
Added Price $29.27
STRIDE Rating 35
Value Change (%) -8.63%
Total Buy0
Total Hold0
Total Sell3
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

AB Science S.A.

AB Science S.A.
Pharmaceuticals, Biotechnology and Life Sciences : Pharmaceuticals.
AB on Euronext Paris.
Price in Euro, all financial data originally reported in Euro.
Founded in 2001, the business is 16 years old.
The business last filed accounts on the 31 Aug, 2016.
Company website: www.ab-science.com
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
France, Small Cap
Market Capitalisation: €510.13M
Total Enterprise Value: Get a demo
AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III studies for the treatment of oncology, inflammatory, and central nervous system diseases. It serves hospitals and specialist physicians. The company was founded in 2001 and is headquartered in Paris, France. Read More
Company Feed
Price & Valuation Info
Price Quote on 13th Apr '17
€14.62 -0.30(-2.01%)
52 Week Range
9.09
19.88
Interactive STRIDE chart with history.
Only available to subscribers.
Get a demo now.
Performance
1 month -0.63 (-4.13%)
year-to-date 0.94 (6.87%)
1 year -3.59 (-19.71%)
Show More Valuation Info
Momentum
vs 52week high 74%
vs 50d SMA 96%
vs 200d SMA110%
STRIDE Valuations
Consider Buy Get a demo
Fair Value Get a demo
Consider Sell Get a demo
Price/Adj. Earnings Get a demo
Price/Adj FCF Get a demo
Price/Adj. TBV Get a demo
Forecast Growth Get a demo
Other Valuations
Price/Book Get a demo
Price/Tangible Book Get a demo
Price/Sales Get a demo
Price/Earnings Get a demo
Price/Free Cashflow Get a demo
EV/EBITDA Get a demo
Dividend Yield Get a demo
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Get a demo
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more